Literature DB >> 24633537

Effect of Urocortin on strength and microarchitecture of osteopenic rat femur.

Mohammad Tezval1, Silja Hansen, Ulrich Schmelz, Marina Komrakova, Klaus Michael Stuermer, Stephan Sehmisch.   

Abstract

As yet there is no evidence of the potential antiosteoporotic effect of Urocortin-1 (UCN), a corticotropin releasing factor related peptide, in vivo. In this study, and for the first time, we investigated the effect of UCN in a rat osteopenia model. Sixty female Sprague-Dawley rats were divided into 5 groups: (1) sham-operated, (2) untreated ovariectomized (OVX) rats, (3) and (4) OVX animals treated for 5 weeks with daily subcutaneous low-dose UCN (3 μg/kg of BW) or high-dose UCN (30 μg/kg of BW) 8 weeks after ovariectomy, and (5) OVX rats treated with daily estrogen (0.2 mg/kg of BW p.o) 8 weeks after ovariectomy for 5 weeks (E). After sacrifice, the femurs were reserved for biomechanical, histomorphometric and ash testing. In the biomechanical test, the high-dose UCN rats showed significantly improved mechanical stiffness (341.6 N/mm) compared with the untreated OVX animals (275.9 N/mm). In the histomorphometric evaluation, the high-dose UCN rats demonstrated an improved trabecular microarchitecture especially and significantly at the distal femur (distal femur Tb.Ar = 41.4% and N.Nd/mm(2) = 26.8, proximal femur Tb.Ar = 71.8% and N.Nd/mm(2) = 28.7) compared with untreated OVX rats (distal femur Tb.Ar = 23.3% and N.Nd/mm(2) = 11.7, proximal femur Tb.Ar = 60.2% and N.Nd/mm(2) = 25.2). Our results show that short-term treatment with UCN seems to have a positive effect on the metaphyseal bone structure and strength of the femur in ovariectomized rats.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24633537     DOI: 10.1007/s00774-014-0578-6

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  21 in total

Review 1.  Widespread tissue distribution and diverse functions of corticotropin-releasing factor and related peptides.

Authors:  Graham C Boorse; Robert J Denver
Journal:  Gen Comp Endocrinol       Date:  2006-01-18       Impact factor: 2.822

2.  Urocortin is a novel regulator of osteoclast differentiation and function through inhibition of a canonical transient receptor potential 1-like cation channel.

Authors:  Charlotte E Combs; Karen Fuller; Hashethra Kumar; Anthony P Albert; Grisha Pirianov; James McCormick; Ian C Locke; Timothy J Chambers; Kevin M Lawrence
Journal:  J Endocrinol       Date:  2011-11-14       Impact factor: 4.286

Review 3.  Neuroendocrinology of the skin.

Authors:  A Slominski; J Wortsman
Journal:  Endocr Rev       Date:  2000-10       Impact factor: 19.871

4.  The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress.

Authors:  Brook Henry; Wylie Vale; Athina Markou
Journal:  J Neurosci       Date:  2006-09-06       Impact factor: 6.167

5.  Peripheral activation of corticotropin-releasing factor receptor 2 inhibits food intake and alters meal structures in mice.

Authors:  Lixin Wang; Andreas Stengel; Miriam Goebel; Vicente Martinez; Guillaume Gourcerol; Jean Rivier; Yvette Taché
Journal:  Peptides       Date:  2010-10-20       Impact factor: 3.750

Review 6.  Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs.

Authors:  Eva M Fekete; Eric P Zorrilla
Journal:  Front Neuroendocrinol       Date:  2006-11-02       Impact factor: 8.606

7.  Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor.

Authors:  J Vaughan; C Donaldson; J Bittencourt; M H Perrin; K Lewis; S Sutton; R Chan; A V Turnbull; D Lovejoy; C Rivier
Journal:  Nature       Date:  1995-11-16       Impact factor: 49.962

8.  Urocortin 1 administered into the hypothalamic supraoptic nucleus inhibits food intake in freely fed and food-deprived rats.

Authors:  A Fatima; S Andrabi; G Wolf; M Engelmann; M G Spina
Journal:  Amino Acids       Date:  2012-10-18       Impact factor: 3.520

9.  Intravenous injection of urocortin 1 induces a CRF2 mediated increase in circulating ghrelin and glucose levels through distinct mechanisms in rats.

Authors:  Lixin Wang; Andreas Stengel; Miriam Goebel-Stengel; Almaas Shaikh; Pu-Qing Yuan; Yvette Taché
Journal:  Peptides       Date:  2012-11-23       Impact factor: 3.750

10.  Improvement of trochanteric bone quality in an osteoporosis model after short-term treatment with parathyroid hormone: a new mechanical test for trochanteric region of rat femur.

Authors:  M Tezval; E K Stuermer; S Sehmisch; T Rack; A Stary; M Stebener; F Konietschke; K M Stuermer
Journal:  Osteoporos Int       Date:  2009-05-13       Impact factor: 4.507

View more
  3 in total

1.  Evaluation of ostarine as a selective androgen receptor modulator in a rat model of postmenopausal osteoporosis.

Authors:  D B Hoffmann; M Komrakova; S Pflug; M von Oertzen; D Saul; L Weiser; T A Walde; M Wassmann; A F Schilling; W Lehmann; S Sehmisch
Journal:  J Bone Miner Metab       Date:  2018-05-21       Impact factor: 2.626

2.  Comparison of parathyroid hormone and strontium ranelate in combination with whole-body vibration in a rat model of osteoporosis.

Authors:  D B Hoffmann; S Sehmisch; A M Hofmann; C Eimer; M Komrakova; D Saul; M Wassmann; K M Stürmer; M Tezval
Journal:  J Bone Miner Metab       Date:  2016-01-29       Impact factor: 2.626

3.  Effect of the lipoxygenase inhibitor baicalein on bone tissue and bone healing in ovariectomized rats.

Authors:  Marina Komrakova; Stephan Sehmisch; Dominik Saul; Marie Weber; Marc Hendrik Zimmermann; Robyn Laura Kosinsky; Daniel Bernd Hoffmann; Björn Menger; Stefan Taudien; Wolfgang Lehmann
Journal:  Nutr Metab (Lond)       Date:  2019-01-11       Impact factor: 4.169

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.